{
  "url": "https://finance.yahoo.com/news/delfi-first-half-2025-earnings-230252728.html?.tsrc=rss",
  "authorsByline": "Simply Wall St",
  "articleId": "dee5f60aec5e47bd823d1bfa96ffe49a",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-14T23:02:52+00:00",
  "addDate": "2025-08-14T23:29:33.426715+00:00",
  "refreshDate": "2025-08-14T23:29:33.426718+00:00",
  "score": 1.0,
  "title": "Delfi First Half 2025 Earnings: EPS: US$0.02 (vs US$0.032 in 1H 2024)",
  "description": "SGX:P34 1 Year Share Price vs Fair Value Explore Delfi's Fair Values from the Community and select yours Delfi...",
  "content": "Explore Delfi's Fair Values from the Community and select yours\n\u2022 Profit margin: 4.7% (down from 7.5% in 1H 2024).\n\u2022 EPS: US$0.02 (down from US$0.032 in 1H 2024).\n\nAI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.\n\nAll figures shown in the chart above are for the trailing 12 month (TTM) period\n\nLooking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Food industry in Singapore.\n\nThe company's shares are down 14% from a week ago.\n\nDon't forget that there may still be risks. For instance, we've identified 2 warning signs for Delfi that you should be aware of.\n\nHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.\n\n\n\nThis article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=3990724&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
    "https://simplywall.st/company/id/A6531DB4-7F69-4843-A423-CAFD50189D96/future?blueprint=3990724&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
    "https://investor-research.typeform.com/to/wvg6MFri#feedback_token=Mzk5MDcyNDpjNzJlZjRiNDZmYmQ4YzE3&company=Delfi&blueprintid=3990724",
    "https://simplywall.st/markets/sg/consumer-staples/food?blueprint=3990724&utm_medium=finance_user&utm_campaign=industry&utm_source=yahoo",
    "https://simplywall.st/stock/sgx/p34?blueprint=3990724&utm_medium=finance_user&utm_campaign=narratives-news-header&utm_source=yahoo&utm_content=narrative-header-stocks-page",
    "https://simplywall.st/company/id/A6531DB4-7F69-4843-A423-CAFD50189D96?blueprint=3990724&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
    "https://au.finance.yahoo.com/quote/P34.SI"
  ],
  "labels": [
    {
      "name": "Roundup"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Simply Wall St",
      "weight": 0.08189081
    },
    {
      "name": "analyst forecasts",
      "weight": 0.07471675
    },
    {
      "name": "historical data",
      "weight": 0.07050886
    },
    {
      "name": "fundamental data",
      "weight": 0.06603099
    },
    {
      "name": "Delfi",
      "weight": 0.06533347
    },
    {
      "name": "early diagnostics",
      "weight": 0.06277736
    },
    {
      "name": "financial advice",
      "weight": 0.061368093
    },
    {
      "name": "Profit margin",
      "weight": 0.06089076
    },
    {
      "name": "drug discovery",
      "weight": 0.054652166
    },
    {
      "name": "long-term focused analysis",
      "weight": 0.052931264
    }
  ],
  "topics": [
    {
      "name": "Markets"
    }
  ],
  "categories": [
    {
      "name": "Finance"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.98388671875
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.98291015625
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.96435546875
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.8388671875
    }
  ],
  "sentiment": {
    "positive": 0.045169782,
    "negative": 0.73615736,
    "neutral": 0.21867284
  },
  "summary": "The article discusses the potential impact of AI technology on healthcare, with a list of 20 companies that are under $10bn in marketcap. The company's shares have fallen by 14% since the start of the week. However, there are two warning signs for investors, including a 4.7% profit margin, and a 3.4% growth forecast for the next three years. The article is based on historical data and analyst forecasts, but does not constitute a recommendation for a purchase or sale.",
  "shortSummary": "Delfish's shares fell due to falling profits, declining profit margins, and market value, highlighting potential for future growth despite strong investor interest.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "f917226606ca4adbaa441f2c92b5c0cc",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=3990724&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
      "text": "Results\n27\nArtificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research. AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription. It powers telemedicine, monitors chronic conditions in real-time, and speeds up drug discovery by analyzing vast datasets for insights into complex diseases. Despite challenges like data privacy, bias, and integration costs, AI\u2019s ability to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery and outcomes.\n27 companies\nCaris Life Sciences\nMarket Cap: US$9.6b\nCaris Life Sciences, Inc, una empresa TechBio de inteligencia artificial, presta servicios de elaboraci\u00f3n de perfiles moleculares en Estados Unidos y a escala internacional.\nCAI\nUS$36.99\n7D\n29.4%\n1Y\nn/a\nRakovina Therapeutics\nMarket Cap: US$11.6m\nRakovina Therapeutics Inc, empresa de investigaci\u00f3n biofarmac\u00e9utica, se dedica a la investigaci\u00f3n y el desarrollo de tratamientos contra el c\u00e1ncer basados en series novedosas de peque\u00f1as mol\u00e9culas diana de la respuesta al da\u00f1o del ADN.\nRKVT.F\nUS$0.41\n7D\n11.4%\n1Y\nn/a\nCosmo Pharmaceuticals\nMarket Cap: US$897.4m\nCosmo Pharmaceuticals N.V. se centra en el desarrollo y la comercializaci\u00f3n de productos para gastroenterolog\u00eda, dermatolog\u00eda y tecnolog\u00eda sanitaria en todo el mundo.\nCMOP.F\nUS$75.00\n7D\n0%\n1Y\n-8.5%\nGubra\nMarket Cap: US$5.8b\nGubra A/S es una empresa biotecnol\u00f3gica dedicada a la investigaci\u00f3n precl\u00ednica por contrato y al descubrimiento de f\u00e1rmacos a base de p\u00e9ptidos para enfermedades metab\u00f3licas y fibr\u00f3ticas en Europa, Norteam\u00e9rica y el resto del mundo.\nGUBR.F\nUS$60.15\n7D\n0%\n1Y\nn/a\nEvaxion\nMarket Cap: US$19.2m\nEvaxion A/S, empresa biotecnol\u00f3gica en fase cl\u00ednica, desarrolla vacunas inmunol\u00f3gicas basadas en inteligencia artificial.\nEVAX\nUS$2.86\n7D\n-2.4%\n1Y\n-81.1%\nImmunoPrecise Antibodies\nMarket Cap: US$91.8m\nOperates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.\nIPA\nUS$2.02\n7D\n9.2%\n1Y\n124.4%\nGeneDx Holdings\nMarket Cap: US$3.5b\nGeneDx Holdings Corp., empresa de gen\u00f3mica, ofrece servicios de pruebas gen\u00e9ticas.\nWGS\nUS$122.88\n7D\n16.0%\n1Y\n273.6%\nEvolent Health\nMarket Cap: US$1.0b\nEvolent Health, Inc. a trav\u00e9s de su filial, presta servicios de gesti\u00f3n de cuidados especializados en los mercados de oncolog\u00eda, cardiolog\u00eda y musculoesquel\u00e9tico en Estados Unidos.\nEVH\nUS$8.82\n7D\n-9.0%\n1Y\n-67.6%\nWELL Health Technologies\nMarket Cap: US$1.3b\nWELL Health Technologies Corp. opera en Canad\u00e1, Estados Unidos e internacionalmente como empresa de atenci\u00f3n sanitaria digital centrada en el profesional sanitario.\nWHTC.F\nUS$3.45\n7D\n-1.4%\n1Y\n-0.1%\nSpectral AI\nMarket Cap: US$56.5m\nAn artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States.\nMDAI\nUS$2.10\n7D\n-12.5%\n1Y\n27.3%\nRevenio Group Oyj\nMarket Cap: US$651.8m\nRevenio Group Oyj, ofrece dispositivos oftalmol\u00f3gicos y soluciones de software para el diagn\u00f3stico del glaucoma, la degeneraci\u00f3n macular y la retinopat\u00eda diab\u00e9tica en Finlandia, Estados Unidos y a escala internacional.\nREVX.F\nUS$31.47\n7D\n0%\n1Y\nn/a\nRadNet\nMarket Cap: US$5.3b\nRadNet, Inc. junto con sus filiales, presta servicios ambulatorios de diagn\u00f3stico por imagen en Estados Unidos y a escala internacional.\nRDNT\nUS$68.75\n7D\n30.9%\n1Y\n8.4%\nCareCloud\nMarket Cap: US$107.9m\nCareCloud, Inc. es una empresa de tecnolog\u00eda de la informaci\u00f3n (TI) sanitaria que ofrece un conjunto de soluciones basadas en la nube y servicios empresariales relacionados a proveedores sanitarios y hospitales, principalmente en Estados Unidos.\nCCLD\nUS$2.56\n7D\n3.6%\n1Y\n11.3%\nSimulations Plus\nMarket Cap: US$292.4m\nSimulations Plus, Inc. desarrolla software de descubrimiento y desarrollo de f\u00e1rmacos para modelado y simulaci\u00f3n, y predicci\u00f3n de propiedades moleculares utilizando tecnolog\u00eda basada en inteligencia artificial y aprendizaje autom\u00e1tico en todo el mundo.\nSLP\nUS$14.20\n7D\n1.0%\n1Y\n-61.1%\nPerimeter Medical Imaging AI\nMarket Cap: US$31.0m\nPerimeter Medical Imaging AI, Inc. es una empresa de tecnolog\u00eda m\u00e9dica que proporciona herramientas avanzadas de diagn\u00f3stico por imagen que responden a necesidades m\u00e9dicas no cubiertas.\nPYNK.F\nUS$0.17\n7D\n-8.4%\n1Y\n-36.9%\nCeriBell\nMarket Cap: US$436.7m\nCeriBell, Inc. opera como una empresa de tecnolog\u00eda m\u00e9dica centrada en transformar el diagn\u00f3stico y la gesti\u00f3n de pacientes con afecciones neurol\u00f3gicas graves en Estados Unidos.\nCBLL\nUS$11.79\n7D\n-6.3%\n1Y\nn/a\nNano-X Imaging\nMarket Cap: US$287.7m\nNano-X Imaging Ltd. desarrolla un dispositivo de im\u00e1genes tomogr\u00e1ficas de calidad comercial con una fuente digital de rayos X.\nNNOX\nUS$4.50\n7D\n-2.6%\n1Y\n-38.0%\nHeartSciences\nMarket Cap: US$8.0m\nHeartSciences Inc, una empresa de tecnolog\u00eda m\u00e9dica, se centra en la aplicaci\u00f3n de tecnolog\u00eda basada en IA a un ECG para ampliar y mejorar la utilidad cl\u00ednica.\nHSCS\nUS$3.50\n7D\n-1.1%\n1Y\n6.8%\nGuardant Health\nMarket Cap: US$7.3b\nGuardant Health, Inc. es una empresa de oncolog\u00eda de precisi\u00f3n que ofrece an\u00e1lisis de sangre y tejidos y conjuntos de datos en Estados Unidos y a escala internacional.\nGH\nUS$60.36\n7D\n19.8%\n1Y\n111.5%\nOmniAb\nMarket Cap: US$251.5m\nOmniAb, Inc. es una empresa biotecnol\u00f3gica que concede licencias de tecnolog\u00eda de investigaci\u00f3n de descubrimientos a empresas farmac\u00e9uticas y biotecnol\u00f3gicas y a instituciones acad\u00e9micas para posibilitar el descubrimiento de terapias en Estados Unidos, Europa, Jap\u00f3n, China y Canad\u00e1.\nOABI\nUS$2.00\n7D\n6.4%\n1Y\n-52.6%\nXtalPi Holdings\nMarket Cap: US$32.9b\nXtalPi Holdings Limited, sociedad de cartera de inversiones, se dedica al suministro de soluciones de rob\u00f3tica y descubrimiento de f\u00e1rmacos en China continental, Estados Unidos e internacionalmente.\nQNTP.F\nUS$1.07\n7D\n56.2%\n1Y\nn/a\nBioXcel Therapeutics\nMarket Cap: US$69.1m\nBioXcel Therapeutics, Inc. junto con su filial OnkosXcel Therapeutics LLC, opera como empresa biofarmac\u00e9utica que utiliza enfoques de inteligencia artificial para desarrollar medicamentos en neurociencia e inmuno-oncolog\u00eda en Estados Unidos.\nBTAI\nUS$4.75\n7D\n39.3%\n1Y\n-56.3%\nNeuroOne Medical Technologies\nMarket Cap: US$42.8m\nNeuroOne Medical Technologies Corporation, empresa de tecnolog\u00eda m\u00e9dica, ofrece soluciones para el registro continuo de electroencefalogramas (cEEG) y estereoelectroencefalograf\u00edas (sEEG) en Estados Unidos.\nNMTC\nUS$0.83\n7D\n9.2%\n1Y\n13.7%\nHealwell AI\nMarket Cap: US$425.2m\nHealwell AI Inc., empresa de inteligencia artificial sanitaria, desarrolla y comercializa sistemas de ayuda a la toma de decisiones cl\u00ednicas en Canad\u00e1, Nueva Zelanda, Australia y el Reino Unido.\nHWAI.F\nUS$1.06\n7D\n3.1%\n1Y\n-27.2%\nAbsci\nMarket Cap: US$450.4m\nAbsci Corporation opera en Estados Unidos como empresa de creaci\u00f3n de f\u00e1rmacos basados en inteligencia artificial (IA) generativa basada en datos.\nABSI\nUS$3.00\n7D\n2.7%\n1Y\n-27.5%\nVeradigm\nMarket Cap: US$798.2m\nVeradigm Inc. es una empresa de tecnolog\u00eda sanitaria que ofrece soluciones inform\u00e1ticas a proveedores de atenci\u00f3n sanitaria, pagadores y mercados biofarmac\u00e9uticos de Estados Unidos e internacionales.\nMDRX\nUS$4.60\n7D\n-3.2%\n1Y\n-51.8%\nPersonalis\nMarket Cap: US$428.3m\nPersonalis, Inc. desarrolla, comercializa y vende pruebas y servicios gen\u00f3micos avanzados contra el c\u00e1ncer en Estados Unidos y a escala internacional.\nPSNL\nUS$4.66\n7D\n2.5%\n1Y\n-8.1%"
    },
    {
      "url": "https://simplywall.st/markets/sg/consumer-staples/food?blueprint=3990724&utm_medium=finance_user&utm_campaign=industry&utm_source=yahoo",
      "text": "Over the last 7 days, the Food industry has remained flat, although notably First Resources gained 8.4%. Furthermore, the industry has been flat for the past year as well. Earnings are forecast to grow by 10% annually.\nHas the Singaporean Food Industry valuation changed over the past few years?\n| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |\n|---|---|---|---|---|---|---|\n| Fri, 15 Aug 2025 | S$32.1b | S$120.4b | S$3.0b | 11.8x | 10.8x | 0.3x |\n| Sun, 13 Jul 2025 | S$30.9b | S$117.6b | S$2.9b | 10.9x | 10.5x | 0.3x |\n| Tue, 10 Jun 2025 | S$31.2b | S$117.9b | S$2.9b | 10.4x | 10.6x | 0.3x |\n| Thu, 08 May 2025 | S$32.4b | S$123.3b | S$3.1b | 10x | 10.4x | 0.3x |\n| Sat, 05 Apr 2025 | S$34.0b | S$127.6b | S$3.2b | 9.4x | 10.6x | 0.3x |\n| Mon, 03 Mar 2025 | S$33.3b | S$128.9b | S$3.2b | 8.5x | 10.3x | 0.3x |\n| Wed, 29 Jan 2025 | S$32.1b | S$124.5b | S$3.3b | 9x | 9.6x | 0.3x |\n| Fri, 27 Dec 2024 | S$32.1b | S$125.1b | S$3.4b | 8.5x | 9.5x | 0.3x |\n| Sun, 24 Nov 2024 | S$32.6b | S$124.2b | S$3.3b | 9.1x | 9.7x | 0.3x |\n| Tue, 22 Oct 2024 | S$34.1b | S$120.7b | S$3.2b | 9.7x | 10.6x | 0.3x |\n| Thu, 19 Sep 2024 | S$32.5b | S$119.0b | S$3.2b | 9.7x | 10.3x | 0.3x |\n| Sat, 17 Aug 2024 | S$32.2b | S$124.5b | S$3.0b | 9.4x | 10.8x | 0.3x |\n| Mon, 15 Jul 2024 | S$32.3b | S$128.2b | S$2.9b | 11x | 11.1x | 0.3x |\n| Wed, 12 Jun 2024 | S$31.8b | S$129.3b | S$3.0b | 10.1x | 10.5x | 0.2x |\n| Fri, 10 May 2024 | S$32.3b | S$129.6b | S$3.1b | 10.9x | 10.4x | 0.2x |\n| Sun, 07 Apr 2024 | S$34.3b | S$128.8b | S$3.0b | 10.6x | 11.3x | 0.3x |\n| Tue, 05 Mar 2024 | S$33.3b | S$128.3b | S$3.1b | 10.4x | 10.9x | 0.3x |\n| Thu, 01 Feb 2024 | S$33.4b | S$133.2b | S$3.8b | 9.3x | 8.7x | 0.3x |\n| Sat, 30 Dec 2023 | S$34.8b | S$131.2b | S$3.8b | 9.5x | 9.2x | 0.3x |\n| Mon, 27 Nov 2023 | S$35.7b | S$133.2b | S$3.9b | 9.5x | 9.2x | 0.3x |\n| Wed, 25 Oct 2023 | S$34.1b | S$136.6b | S$4.2b | 8.9x | 8.1x | 0.2x |\n| Fri, 22 Sep 2023 | S$35.7b | S$136.7b | S$4.2b | 9.4x | 8.5x | 0.3x |\n| Sun, 20 Aug 2023 | S$35.1b | S$135.6b | S$4.1b | 10.1x | 8.5x | 0.3x |\n| Tue, 18 Jul 2023 | S$36.3b | S$138.3b | S$5.2b | 8.8x | 6.9x | 0.3x |\n| Thu, 15 Jun 2023 | S$38.2b | S$140.4b | S$5.3b | 8.7x | 7.2x | 0.3x |\n| Sat, 13 May 2023 | S$38.0b | S$139.9b | S$5.4b | 9.8x | 7x | 0.3x |\n| Mon, 10 Apr 2023 | S$39.5b | S$139.8b | S$5.5b | 9.5x | 7.2x | 0.3x |\n| Wed, 08 Mar 2023 | S$38.4b | S$141.0b | S$5.6b | 8.1x | 6.9x | 0.3x |\n| Fri, 03 Feb 2023 | S$38.9b | S$135.7b | S$5.4b | 8.4x | 7.2x | 0.3x |\n| Sun, 01 Jan 2023 | S$39.2b | S$138.9b | S$5.5b | 7.2x | 7.1x | 0.3x |\n| Tue, 29 Nov 2022 | S$39.5b | S$142.4b | S$5.6b | 7.2x | 7x | 0.3x |\n| Thu, 27 Oct 2022 | S$35.8b | S$145.6b | S$5.6b | 6.2x | 6.4x | 0.2x |\n| Sat, 24 Sep 2022 | S$38.8b | S$146.1b | S$5.6b | 6.7x | 6.9x | 0.3x |\n| Mon, 22 Aug 2022 | S$40.7b | S$143.4b | S$5.5b | 7x | 7.3x | 0.3x |\n7.3x\nWhich industries have driven the changes within the Singaporean Consumer Staples industry?\n| SG Market | 0.99% | |\n| Consumer Staples | 0.58% | |\n| Food | 0.37% | |\n| Agricultural Products | 0.95% | |\n| Packaged Foods and Meats | -1.99% |\nWhich companies have driven the market over the last 7 days?\n| Company | Last Price | 7D | 1Y | Valuation | |\n|---|---|---|---|---|---|\n| EB5 First Resources | S$1.68 | 8.4% +S$201.4m | 20.0% | PE8.3x | |\n| P8Z Bumitama Agri | S$0.92 | 12.3% +S$173.4m | 29.8% | PE7.4x | |\n| E5H Golden Agri-Resources | S$0.27 | 3.9% +S$126.8m | 0% | PE7.2x | |\n| MV4 Mewah International | S$0.27 | 1.9% +S$7.5m | -1.8% | PE8.2x | |\n| 5JS Indofood Agri Resources | S$0.35 | 1.4% +S$7.0m | 22.4% | PE5.4x |"
    },
    {
      "url": "https://simplywall.st/company/id/A6531DB4-7F69-4843-A423-CAFD50189D96/future?blueprint=3990724&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "Delfi Future Growth\nFuture criteria checks 2/6\nDelfi is forecast to grow earnings and revenue by 10.5% and 3.4% per annum respectively. EPS is expected to grow by 10% per annum. Return on equity is forecast to be 11% in 3 years.\nKey information\n10.5%\nEarnings growth rate\n10.04%\nEPS growth rate\n| Food earnings growth | 10.5% |\n| Revenue growth rate | 3.4% |\n| Future return on equity | 10.96% |\n| Analyst coverage | Low |\n| Last updated | 13 Aug 2025 |\nRecent future growth updates\nRecent updates\nDelfi (SGX:P34) Seems To Use Debt Quite Sensibly\nAug 13Subdued Growth No Barrier To Delfi Limited (SGX:P34) With Shares Advancing 25%\nJul 22Delfi's (SGX:P34) Returns Have Hit A Wall\nApr 08Delfi (SGX:P34) Will Pay A Smaller Dividend Than Last Year\nMar 02Delfi's (SGX:P34) Dividend Will Be Reduced To $0.0272\nAug 15Delfi's (SGX:P34) Dividend Will Be $0.0302\nApr 24Delfi (SGX:P34) Will Pay A Dividend Of $0.0302\nApr 07Delfi Limited Just Missed EPS By 9.9%: Here's What Analysts Think Will Happen Next\nMar 03An Intrinsic Calculation For Delfi Limited (SGX:P34) Suggests It's 20% Undervalued\nNov 20Delfi (SGX:P34) Has Announced That It Will Be Increasing Its Dividend To $0.0273\nAug 09The Trend Of High Returns At Delfi (SGX:P34) Has Us Very Interested\nAug 01Should You Be Adding Delfi (SGX:P34) To Your Watchlist Today?\nMay 04Delfi's (SGX:P34) Shareholders Will Receive A Bigger Dividend Than Last Year\nApr 04Delfi (SGX:P34) Will Pay A Larger Dividend Than Last Year At $0.0218\nAug 12Delfi (SGX:P34) Is Increasing Its Dividend To S$0.021\nApr 17Delfi's (SGX:P34) Dividend Will Be Increased To S$0.021\nApr 03Delfi (SGX:P34) Will Pay A Larger Dividend Than Last Year At S$0.021\nFeb 24Delfi's (SGX:P34) Shareholders Will Receive A Smaller Dividend Than Last Year\nAug 12Is Delfi (SGX:P34) A Risky Investment?\nJun 11How Does Delfi Limited (SGX:P34) Fare As A Dividend Stock?\nMay 07We Think You Can Look Beyond Delfi's (SGX:P34) Lackluster Earnings\nApr 18What Do The Returns On Capital At Delfi (SGX:P34) Tell Us?\nMar 12Does Delfi (SGX:P34) Have A Healthy Balance Sheet?\nFeb 26Have Insiders Been Buying Delfi Limited (SGX:P34) Shares?\nFeb 01Could The Delfi Limited (SGX:P34) Ownership Structure Tell Us Something Useful?\nJan 12Here's What You Should Know About Delfi Limited's (SGX:P34) 4.3% Dividend Yield\nDec 24Delfi Limited's (SGX:P34) Stock Is Going Strong: Is the Market Following Fundamentals?\nDec 11What Do The Returns On Capital At Delfi (SGX:P34) Tell Us?\nNov 24Earnings and Revenue Growth Forecasts\n| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |\n|---|---|---|---|---|---|\n| 12/31/2027 | 545 | 34 | 9 | 39 | 2 |\n| 12/31/2026 | 520 | 30 | 12 | 39 | 3 |\n| 12/31/2025 | 504 | 27 | 12 | 39 | 3 |\n| 6/30/2025 | 501 | 27 | 64 | 73 | N/A |\n| 3/31/2025 | 502 | 30 | 44 | 63 | N/A |\n| 12/31/2024 | 503 | 34 | 24 | 53 | N/A |\n| 9/30/2024 | 509 | 37 | 14 | 46 | N/A |\n| 6/30/2024 | 516 | 41 | 4 | 39 | N/A |\n| 3/31/2024 | 527 | 43 | 3 | 32 | N/A |\n| 12/31/2023 | 538 | 46 | 2 | 25 | N/A |\n| 9/30/2023 | 526 | 48 | -1 | 19 | N/A |\n| 6/30/2023 | 514 | 50 | -3 | 13 | N/A |\n| 3/31/2023 | 496 | 47 | 0 | 11 | N/A |\n| 12/31/2022 | 477 | 44 | 4 | 8 | N/A |\n| 9/30/2022 | 459 | 40 | 23 | 27 | N/A |\n| 6/30/2022 | 441 | 36 | 43 | 46 | N/A |\n| 3/31/2022 | 423 | 33 | 58 | 62 | N/A |\n| 12/31/2021 | 405 | 29 | 74 | 77 | N/A |\n| 9/30/2021 | 402 | 24 | 67 | 71 | N/A |\n| 6/30/2021 | 398 | 19 | 60 | 65 | N/A |\n| 3/31/2021 | 392 | 18 | 49 | 54 | N/A |\n| 12/31/2020 | 385 | 17 | 37 | 42 | N/A |\n| 9/30/2020 | 379 | 21 | 27 | 36 | N/A |\n| 6/30/2020 | 397 | 24 | 29 | 38 | N/A |\n| 3/31/2020 | 411 | 24 | 34 | 45 | N/A |\n| 12/31/2019 | 441 | 28 | 21 | 32 | N/A |\n| 9/30/2019 | 461 | 25 | 20 | 28 | N/A |\n| 6/30/2019 | 451 | 23 | 16 | 25 | N/A |\n| 3/31/2019 | 448 | 23 | N/A | 13 | N/A |\n| 12/31/2018 | 427 | 21 | N/A | 12 | N/A |\n| 9/30/2018 | 419 | 19 | N/A | 14 | N/A |\n| 6/30/2018 | 404 | 19 | N/A | 19 | N/A |\n| 3/31/2018 | 395 | 22 | N/A | 13 | N/A |\n| 12/31/2017 | 381 | 20 | N/A | 25 | N/A |\n| 9/30/2017 | 387 | 21 | N/A | 41 | N/A |\n| 6/30/2017 | 386 | 23 | N/A | 57 | N/A |\n| 3/31/2017 | 392 | 23 | N/A | 61 | N/A |\n| 12/31/2016 | 402 | 26 | N/A | 60 | N/A |\n| 9/30/2016 | 397 | 23 | N/A | 54 | N/A |\n| 6/30/2016 | 395 | -3 | N/A | 39 | N/A |\n| 3/31/2016 | 403 | -4 | N/A | 35 | N/A |\n| 12/31/2015 | 406 | -5 | N/A | 43 | N/A |\n| 9/30/2015 | 437 | 7 | N/A | 29 | N/A |\n| 6/30/2015 | 471 | 38 | N/A | 35 | N/A |\n| 3/31/2015 | 487 | 43 | N/A | 42 | N/A |\n| 12/31/2014 | 504 | 49 | N/A | 22 | N/A |\n| 9/30/2014 | 503 | 52 | N/A | 47 | N/A |\nAnalyst Future Growth Forecasts\nEarnings vs Savings Rate: P34's forecast earnings growth (10.5% per year) is above the savings rate (2.4%).\nEarnings vs Market: P34's earnings (10.5% per year) are forecast to grow faster than the SG market (5.9% per year).\nHigh Growth Earnings: P34's earnings are forecast to grow, but not significantly.\nRevenue vs Market: P34's revenue (3.4% per year) is forecast to grow slower than the SG market (3.8% per year).\nHigh Growth Revenue: P34's revenue (3.4% per year) is forecast to grow slower than 20% per year.\nEarnings per Share Growth Forecasts\nFuture Return on Equity\nFuture ROE: P34's Return on Equity is forecast to be low in 3 years time (11%).\nDiscover growth companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/14 22:59 |\n| End of Day Share Price | 2025/08/14 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nDelfi Limited is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Wee Kuang Tay | CGS International |\n| David Mak | CGS International |\n| Patrick Yau | Citigroup Inc |"
    },
    {
      "url": "https://simplywall.st/stock/sgx/p34?blueprint=3990724&utm_medium=finance_user&utm_campaign=narratives-news-header&utm_source=yahoo&utm_content=narrative-header-stocks-page",
      "text": "Delfi Limited, an investment holding company, manufactures, markets, distributes, and sells chocolate, chocolate confectionery, and consumer products in Indonesia, the Philippines, Malaysia, Singapore, and internationally. The company\u2019s products include chocolate bars, chocolate rice, moulded chocolates, drag\u00e9es, chocolate spreads, enrobed wafers, chocolate biscuits, sandwich biscuits, and beverages. It also offers snacks, confectionery, breakfast, beverage, and grocery products, as well as provides healthcare, administrative, and investment holding services. It markets its products under the SilverQueen, Ceres, Delfi, Cha Cha, Take-It, Van Houten, Top, Selamat, Goya, and Knick Knacks brand names through hypermarkets, supermarkets, wholesalers, and chain stores. The company was formerly known as Petra Foods Limited and changed its name to Delfi Limited in May 2016. Delfi Limited was incorporated in 1984 and is headquartered in Singapore.\nSingaporean Market Performance\n7D7 Days: 1.0%\n3M3 Months: 11.1%\n1Y1 Year: 27.5%\nYTDYear to Date: 13.6%\nIn the last week, the market has been flat, with a notable exception in the Utilities sector dropping 14%. More promisingly, the market is up 27% over the past year. Earnings are forecast to grow by 5.9% annually. Market details \u203a\nThis week, we are weighing up the potential productivity gains vs job losses and economic disruption that the global economy could face over the next decade and beyond."
    },
    {
      "url": "https://simplywall.st/company/id/A6531DB4-7F69-4843-A423-CAFD50189D96?blueprint=3990724&utm_medium=finance_user&utm_campaign=conclusion&utm_source=yahoo",
      "text": "Delfi (P34) Stock Overview\nAn investment holding company, manufactures, markets, distributes, and sells chocolate, chocolate confectionery, and consumer products in Indonesia, the Philippines, Malaysia, Singapore, and internationally. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 2/6 |\n| Future Growth | 2/6 |\n| Past Performance | 2/6 |\n| Financial Health | 6/6 |\n| Dividends | 3/6 |\nP34 Community Fair Values\nSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.\nDelfi Limited Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | S$0.76 |\n| 52 Week High | S$0.91 |\n| 52 Week Low | S$0.65 |\n| Beta | 0.052 |\n| 1 Month Change | -7.36% |\n| 3 Month Change | 4.86% |\n| 1 Year Change | -9.04% |\n| 3 Year Change | -3.21% |\n| 5 Year Change | 0.67% |\n| Change since IPO | -12.72% |\nRecent News & Updates\nDelfi (SGX:P34) Seems To Use Debt Quite Sensibly\nAug 13Subdued Growth No Barrier To Delfi Limited (SGX:P34) With Shares Advancing 25%\nJul 22Recent updates\nDelfi (SGX:P34) Seems To Use Debt Quite Sensibly\nAug 13Subdued Growth No Barrier To Delfi Limited (SGX:P34) With Shares Advancing 25%\nJul 22Delfi's (SGX:P34) Returns Have Hit A Wall\nApr 08Delfi (SGX:P34) Will Pay A Smaller Dividend Than Last Year\nMar 02Delfi's (SGX:P34) Dividend Will Be Reduced To $0.0272\nAug 15Delfi's (SGX:P34) Dividend Will Be $0.0302\nApr 24Delfi (SGX:P34) Will Pay A Dividend Of $0.0302\nApr 07Delfi Limited Just Missed EPS By 9.9%: Here's What Analysts Think Will Happen Next\nMar 03An Intrinsic Calculation For Delfi Limited (SGX:P34) Suggests It's 20% Undervalued\nNov 20Delfi (SGX:P34) Has Announced That It Will Be Increasing Its Dividend To $0.0273\nAug 09The Trend Of High Returns At Delfi (SGX:P34) Has Us Very Interested\nAug 01Should You Be Adding Delfi (SGX:P34) To Your Watchlist Today?\nMay 04Delfi's (SGX:P34) Shareholders Will Receive A Bigger Dividend Than Last Year\nApr 04Delfi (SGX:P34) Will Pay A Larger Dividend Than Last Year At $0.0218\nAug 12Delfi (SGX:P34) Is Increasing Its Dividend To S$0.021\nApr 17Delfi's (SGX:P34) Dividend Will Be Increased To S$0.021\nApr 03Delfi (SGX:P34) Will Pay A Larger Dividend Than Last Year At S$0.021\nFeb 24Delfi's (SGX:P34) Shareholders Will Receive A Smaller Dividend Than Last Year\nAug 12Is Delfi (SGX:P34) A Risky Investment?\nJun 11How Does Delfi Limited (SGX:P34) Fare As A Dividend Stock?\nMay 07We Think You Can Look Beyond Delfi's (SGX:P34) Lackluster Earnings\nApr 18What Do The Returns On Capital At Delfi (SGX:P34) Tell Us?\nMar 12Does Delfi (SGX:P34) Have A Healthy Balance Sheet?\nFeb 26Have Insiders Been Buying Delfi Limited (SGX:P34) Shares?\nFeb 01Could The Delfi Limited (SGX:P34) Ownership Structure Tell Us Something Useful?\nJan 12Here's What You Should Know About Delfi Limited's (SGX:P34) 4.3% Dividend Yield\nDec 24Delfi Limited's (SGX:P34) Stock Is Going Strong: Is the Market Following Fundamentals?\nDec 11What Do The Returns On Capital At Delfi (SGX:P34) Tell Us?\nNov 24Shareholder Returns\n| P34 | SG Food | SG Market | |\n|---|---|---|---|\n| 7D | -14.2% | 0.4% | 1.0% |\n| 1Y | -9.0% | 3.0% | 27.5% |\nReturn vs Industry: P34 underperformed the SG Food industry which returned 3% over the past year.\nReturn vs Market: P34 underperformed the SG Market which returned 27.5% over the past year.\nPrice Volatility\n| P34 volatility | |\n|---|---|\n| P34 Average Weekly Movement | 5.0% |\n| Food Industry Average Movement | 3.9% |\n| Market Average Movement | 5.3% |\n| 10% most volatile stocks in SG Market | 16.7% |\n| 10% least volatile stocks in SG Market | 2.5% |\nStable Share Price: P34 has not had significant price volatility in the past 3 months compared to the SG market.\nVolatility Over Time: P34's weekly volatility (5%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 1984 | n/a | John Chuang | www.delfilimited.com |\nDelfi Limited, an investment holding company, manufactures, markets, distributes, and sells chocolate, chocolate confectionery, and consumer products in Indonesia, the Philippines, Malaysia, Singapore, and internationally. The company\u2019s products include chocolate bars, chocolate rice, moulded chocolates, drag\u00e9es, chocolate spreads, enrobed wafers, chocolate biscuits, sandwich biscuits, and beverages. It also offers snacks, confectionery, breakfast, beverage, and grocery products, as well as provides healthcare, administrative, and investment holding services.\nDelfi Limited Fundamentals Summary\n| P34 fundamental statistics | |\n|---|---|\n| Market cap | S$461.42m |\n| Earnings (TTM) | S$34.03m |\n| Revenue (TTM) | S$642.12m |\nIs P34 overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| P34 income statement (TTM) | |\n|---|---|\n| Revenue | US$501.40m |\n| Cost of Revenue | US$367.35m |\n| Gross Profit | US$134.05m |\n| Other Expenses | US$107.48m |\n| Earnings | US$26.57m |\nLast Reported Earnings\nJun 30, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | 0.043 |\n| Gross Margin | 26.73% |\n| Net Profit Margin | 5.30% |\n| Debt/Equity Ratio | 7.4% |\nHow did P34 perform over the long term?\nSee historical performance and comparisonDividends\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/14 22:59 |\n| End of Day Share Price | 2025/08/14 00:00 |\n| Earnings | 2025/06/30 |\n| Annual Earnings | 2024/12/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nDelfi Limited is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Wee Kuang Tay | CGS International |\n| David Mak | CGS International |\n| Patrick Yau | Citigroup Inc |"
    }
  ],
  "argos_summary": "Delfi Limited has experienced a decline in profit margin and earnings per share (EPS) in the first half of 2024, with a profit margin of 4.7% and EPS of US$0.02. The company is projected to grow revenue by 3.4% annually over the next three years, which is slower than the overall growth forecast for the food industry in Singapore. Despite a recent 14% drop in share price, Delfi's earnings are expected to grow at a rate of 10.5% per year, although there are identified risks associated with the investment.",
  "argos_id": "E8YT52SZ3"
}